McKenzie Brent S, Corbett Alexandra J, Johnson Susan, Brady Jamie L, Pleasance Jill, Kramer David R, Boyle Jefferey S, Jackson David C, Strugnell Richard A, Lew Andrew M
The Walter and Eliza Hall Institute of Medical Research and Co-operative Research Centre for Vaccine Technology, 1G Royal Parade, Parkville 3050, Australia.
Int Immunol. 2004 Nov;16(11):1613-22. doi: 10.1093/intimm/dxh163. Epub 2004 Oct 5.
Induction of mucosal immunity, particularly to subunit vaccines, has been problematic. The primary hurdle to successful mucosal vaccination is the effective delivery of vaccine antigen to the mucosal associated lymphoid tissue. Physical and chemical barriers restrict antigen access and, moreover, immune responses induced in the mucosa can be biased towards tolerance or non-reactivity. We proposed that these difficulties could be circumvented by targeting antigen to the gastrointestinal associated lymphoid tissue via systemic (parenteral) rather than alimentary routes, using antibodies specific for the mucosal addressin cellular adhesion molecule-1 (MAdCAM). After intravenous or intramuscular injection of such rat antibodies in mice, we found a greatly enhanced (up to 3 logs) anti-rat antibody response. MAdCAM targeting induces a rapid IgA antibody response in the gut and vastly improves the systemic antibody response. Targeting also enhanced T cell proliferation and cytokine responses. Parenteral targeting of mucosal addressins may represent a generic technique for bypassing mucosal barriers and eliminating the need for adjuvants in the induction of proximal and systemic immunity.
诱导黏膜免疫,尤其是针对亚单位疫苗的免疫,一直存在问题。成功进行黏膜疫苗接种的主要障碍是将疫苗抗原有效递送至黏膜相关淋巴组织。物理和化学屏障限制了抗原的进入,此外,在黏膜中诱导的免疫反应可能倾向于耐受或无反应性。我们提出,通过使用针对黏膜地址素细胞黏附分子-1(MAdCAM)的特异性抗体,经全身(肠胃外)而非消化道途径将抗原靶向胃肠道相关淋巴组织,可以规避这些困难。在小鼠静脉或肌肉注射此类大鼠抗体后,我们发现抗大鼠抗体反应大幅增强(高达3个对数)。MAdCAM靶向可在肠道诱导快速的IgA抗体反应,并极大地改善全身抗体反应。靶向还增强了T细胞增殖和细胞因子反应。黏膜地址素的肠胃外靶向可能是一种绕过黏膜屏障并消除在诱导近端和全身免疫中使用佐剂需求的通用技术。